Lastly, combined blockade of UBR5 and PD-L1 leads to a synergistic therapeutic benefit in eradicating tumor growth and prolong the survival or even to a potential cure (Figure 3), although we need to more rigorously corroborate the synergism by other ways of targeting of UBR5 and PD-L1 than the genetic means. Here, CD274 is linked to neoplasm.